Cargando…

Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions

AIM: To assess the levels of different immune modulators in patients with hepatocellular carcinoma (HCC), in relation to other hepatic diseases. METHODS: Eighty-eight patients were included in the current study and represented patients with HCC (20), liver cirrhosis (28) and chronic hepatitis (CH; 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Zekri, Abdel-Rahman N, El Deeb, Somaya, Bahnassy, Abeer A, Badr, Abeer M, Abdellateif, Mona S, Esmat, Gamal, Salama, Hosny, Mohanad, Marwa, El-dien, Ahmed Esam, Rabah, Shimaa, Abd Elkader, Assmaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859225/
https://www.ncbi.nlm.nih.gov/pubmed/29568203
http://dx.doi.org/10.3748/wjg.v24.i11.1228
_version_ 1783307778793668608
author Zekri, Abdel-Rahman N
El Deeb, Somaya
Bahnassy, Abeer A
Badr, Abeer M
Abdellateif, Mona S
Esmat, Gamal
Salama, Hosny
Mohanad, Marwa
El-dien, Ahmed Esam
Rabah, Shimaa
Abd Elkader, Assmaa
author_facet Zekri, Abdel-Rahman N
El Deeb, Somaya
Bahnassy, Abeer A
Badr, Abeer M
Abdellateif, Mona S
Esmat, Gamal
Salama, Hosny
Mohanad, Marwa
El-dien, Ahmed Esam
Rabah, Shimaa
Abd Elkader, Assmaa
author_sort Zekri, Abdel-Rahman N
collection PubMed
description AIM: To assess the levels of different immune modulators in patients with hepatocellular carcinoma (HCC), in relation to other hepatic diseases. METHODS: Eighty-eight patients were included in the current study and represented patients with HCC (20), liver cirrhosis (28) and chronic hepatitis (CH; 25), and normal controls (NC; 15). Peripheral blood was isolated for immunophenotyping of active myeloid dendritic cells (mDCs; CD1c and CD40), mature inactive myeloid cells (CD1c and HLA), active plasmacytoid cells (pDCs; CD303 and CD40), mature inactive pDCs (CD30 and HLA), active natural killer (NK) cells (CD56 and CD161), active NK cells (CD56 and CD314) and inactive NK cells (CD56 and CD158) was done by flow cytometry. Serum levels of interleukin (IL)-2, IL-10, IL-12, IL-1β, interferon (IFN)-α, IFN-γ and tumor necrosis factor (TNF)-αR2 were assessed by ELISA. RESULTS: Active mDCs (CD1C+/CD40+) and inactive mDCs (CD1c+/HLA+) were significantly decreased in HCC patients in relation to NC (P < 0.001). CD40+ expression on active pDCs was decreased in HCC patients (P < 0.001), and its level was not significantly changed among other groups. Inactive pDCs (CD303+/HLA+), inactive NKs (CD56+/CD158+) and active NKs (CD56+/CD161+) were not statistically changed among the four groups studied; however, the latter was increased in CH (P < 0.05). NKG2D was statistically decreased in HCC, CH and cirrhosis (P < 0.001), and it was not expressed in 63% (12/20) of HCC patients. There was significant decrease of IL-2, IFN-α and IFN-γ (P < 0.001), and a significant increase in IL-10, IL-1β, and TNF-αR2 (P <0.01, P < 0.001 and P < 0.001; respectively) in HCC patients. There was inverted correlation between IL-12 and IL-1β in HCC (r = -0.565, P < 0.01), with a strong correlation between pDCs (CD303+/CD40+) and NKs (CD56+/CD161+; r = 0.512, P < 0.05) as well as inactive mDCs (CD1c+/HLA+) and inactive NK cells (CD56+/CD158+; r = 0.945, P < 0.001). CONCLUSION: NKG2D, CD40, IL-2 and IL-10 are important modulators in the development and progression of HCC.
format Online
Article
Text
id pubmed-5859225
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-58592252018-03-22 Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions Zekri, Abdel-Rahman N El Deeb, Somaya Bahnassy, Abeer A Badr, Abeer M Abdellateif, Mona S Esmat, Gamal Salama, Hosny Mohanad, Marwa El-dien, Ahmed Esam Rabah, Shimaa Abd Elkader, Assmaa World J Gastroenterol Retrospective Cohort Study AIM: To assess the levels of different immune modulators in patients with hepatocellular carcinoma (HCC), in relation to other hepatic diseases. METHODS: Eighty-eight patients were included in the current study and represented patients with HCC (20), liver cirrhosis (28) and chronic hepatitis (CH; 25), and normal controls (NC; 15). Peripheral blood was isolated for immunophenotyping of active myeloid dendritic cells (mDCs; CD1c and CD40), mature inactive myeloid cells (CD1c and HLA), active plasmacytoid cells (pDCs; CD303 and CD40), mature inactive pDCs (CD30 and HLA), active natural killer (NK) cells (CD56 and CD161), active NK cells (CD56 and CD314) and inactive NK cells (CD56 and CD158) was done by flow cytometry. Serum levels of interleukin (IL)-2, IL-10, IL-12, IL-1β, interferon (IFN)-α, IFN-γ and tumor necrosis factor (TNF)-αR2 were assessed by ELISA. RESULTS: Active mDCs (CD1C+/CD40+) and inactive mDCs (CD1c+/HLA+) were significantly decreased in HCC patients in relation to NC (P < 0.001). CD40+ expression on active pDCs was decreased in HCC patients (P < 0.001), and its level was not significantly changed among other groups. Inactive pDCs (CD303+/HLA+), inactive NKs (CD56+/CD158+) and active NKs (CD56+/CD161+) were not statistically changed among the four groups studied; however, the latter was increased in CH (P < 0.05). NKG2D was statistically decreased in HCC, CH and cirrhosis (P < 0.001), and it was not expressed in 63% (12/20) of HCC patients. There was significant decrease of IL-2, IFN-α and IFN-γ (P < 0.001), and a significant increase in IL-10, IL-1β, and TNF-αR2 (P <0.01, P < 0.001 and P < 0.001; respectively) in HCC patients. There was inverted correlation between IL-12 and IL-1β in HCC (r = -0.565, P < 0.01), with a strong correlation between pDCs (CD303+/CD40+) and NKs (CD56+/CD161+; r = 0.512, P < 0.05) as well as inactive mDCs (CD1c+/HLA+) and inactive NK cells (CD56+/CD158+; r = 0.945, P < 0.001). CONCLUSION: NKG2D, CD40, IL-2 and IL-10 are important modulators in the development and progression of HCC. Baishideng Publishing Group Inc 2018-03-21 2018-03-21 /pmc/articles/PMC5859225/ /pubmed/29568203 http://dx.doi.org/10.3748/wjg.v24.i11.1228 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Zekri, Abdel-Rahman N
El Deeb, Somaya
Bahnassy, Abeer A
Badr, Abeer M
Abdellateif, Mona S
Esmat, Gamal
Salama, Hosny
Mohanad, Marwa
El-dien, Ahmed Esam
Rabah, Shimaa
Abd Elkader, Assmaa
Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
title Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
title_full Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
title_fullStr Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
title_full_unstemmed Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
title_short Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
title_sort role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859225/
https://www.ncbi.nlm.nih.gov/pubmed/29568203
http://dx.doi.org/10.3748/wjg.v24.i11.1228
work_keys_str_mv AT zekriabdelrahmann roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT eldeebsomaya roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT bahnassyabeera roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT badrabeerm roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT abdellateifmonas roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT esmatgamal roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT salamahosny roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT mohanadmarwa roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT eldienahmedesam roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT rabahshimaa roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions
AT abdelkaderassmaa roleofrelevantimmunemodulatorsandcytokinesinhepatocellularcarcinomaandpremalignanthepaticlesions